The Invention relates to a spray formulation is appropriate for use in patients of COPD by means of a pressurized Metered Dose Inhaler (pmdl), which includes glycopyrronium bromide in combination with formoterol.The formulation also includes a HFA propellant, a co Solvent, and a quantity of inorganic acid is sufficient to stabilize both the component of glycopyrronium bromide as the formoterol. Optionally, the formulation also includes beclomethasone Dipropionate.Farmaceutska kompozicija koja sadržl:(a) glikopironium bromid u dozi u opsegu od 0.5-100 µg po aktiviranju； i(b) formoterol ili njegovu so u dozi u opsegu od 1-25 µg po aktiviranju；rastvorenu u HFA propelantu i korastvaraču, naznačenu time da navedena kompozicija sadrži količinu 1M HCl u rasponu od 0,1 - 0,3 µg/µl.Prijava sadrži još 13 patentnih zahteva.
